4229 -- Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015 | Poliscope

Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015

4229

114th Congress

Crime and Law Enforcement

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

December 10, 2015

Latest Action

January 15, 2016

Primary Sponsor

John KatkoRepublican(NY)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

71pct

36d open

vs 6,526 other HR bills in the 114th — cohort avg 56d

Summary

Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015 This bill amends the Controlled Substances Act to include in the definition of a "controlled substance analogue" a substance designated as such by the Controlled Substance Analogue Committee (established by this bill). It directs the Drug Enforcement Administration (DEA) to establish such Committee as an interagency committee headed by the DEA and comprised of scientific experts in the fields of chemistry and pharmacology from the DEA, the National Institute on Drug Abuse, the Centers for Disease Control and Prevention, and any other federal agency determined by the DEA to be appropriate. The Committee may designate, and shall establish and maintain a list of, controlled substance analogues determined to be similar to a schedule I or II controlled substance in either chemical structure or predictive effect on the body in such a manner as to make it likely that the substance will, or can be reasonably expected to, have a potential for abuse. The DEA must publish a description of each designation made by the Committee. The bill amends the Controlled Substances Import and Export Act to prohibit the importation of any controlled substance analogue except pursuant to such notification or declaration as the DEA may prescribe. It directs the U.S. Sentencing Commission to review and, if appropriate, amend the federal sentencing guidelines and policy statements to ensure that they provide adequate penalties for any offense involving the unlawful manufacturing, importing, exporting, or trafficking of controlled substance analogues and similar offenses.

Lobbying filings that explicitly cite this bill (4)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (2)

VAN SCOYOC ASSOCIATES (3)AMERICAN MEDICAL ASSOCIATION (1)

COLLEGE ON PROBLEMS OF DRUG DEPENDENCEclient→VAN SCOYOC ASSOCIATES

2016 · fourth_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R.5926/S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment Biomedical innovation legislation (Senate draft) H.R.6, 21st Century Cures Act, Medical research issues. H.R.34, 21st Century Cures Act, Medical research issues. Drug abuse research and treatment related issues: H.R.3537, Synthetic Drug Control Act of 2015 Public Law 114-198, Comprehensive Addiction and Recovery Act of 2016 S.3224/H.R.5934, Dangerous Synthetic Drug Control Act of 2016 S.36/H.R.4229, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015

Subjects (7)

Administrative law and regulatory procedures

Criminal procedure and sentencing

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Executive agency funding and structure

Trade restrictions

U.S. Sentencing Commission

Actions (4)

January 15, 2016

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

December 11, 2015

Referred to the Subcommittee on Health.

December 10, 2015

Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Congress.gov source codes: H11100, H11100-A

December 10, 2015

Introduced in House

Congress.gov source codes: 1000, Intro-H

Committees

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred to	December 10, 2015
Energy and Commerce Committee	House	Referred to	December 10, 2015

Text Versions

Version	Date	Links
Introduced in House	December 10, 2015	XML

Cosponsors (34)

Name	Party	State
Alcee L. Hastings	Democratic	FL
Ann M. Kuster	Democratic	NH
Barbara Comstock	Republican	VA

Related Bills (1)

Bill	Congress	Relationship
S 36	114th	Identical bill

Similar Bills (AI)

Bills with similar content found using semantic analysis.

700

118th

Expressing support for the designation of September 2023 as "National Prostate Cancer Awareness Month".

1206

118th

Expressing support for the designation of May 2024 as "Mental Health Awareness Month".

507

119th

Expressing support for the designation of June 10 as "FSGS Awareness Day".

Sources: Congress.gov

COLLEGE ON PROBLEMS OF DRUG DEPENDENCEclient→VAN SCOYOC ASSOCIATES

2016 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2017, provisions relating to NIH and drug abuse and treatment H.R.6, 21st Century Cures Act, Medical research issues. Drug abuse research and treatment related issues: S. 2030, The Advancing Targeted Therapies for Rare Diseases Act of 2015 S. 1622, The FDA Device Accountability Act of 2015 S. 2014, Next Generation Researchers Act S. 800, The Enhancing the Stature and Visibility of Medical Rehabilitation Research at NIH Act S. 849, Advancing Research for Neurological Diseases Act of 2015 S. 2503, Preventing Superbugs and Protecting Patients Act S. 2511, Improving Health Information Technology S. 1878, The Advancing Hope Act of 2015 S. 1077, The Advancing Breakthrough Medical Devices for Patients Act of 2015 S. 1101, The Medical Electronic Data Technology Enhancement for Consumers Health Act S. 2055, The Medical Countermeasures Innovation Act of 2015 S. 1767, The Combination Products Innovation Act of 2015 S. 1597, Patient Focused Impact Assessment Act of 2015 S. 2512, Adding Zika Virus to the FDA Priority Review Voucher Program Act S. 2700, FDA and NIH Workforce Authorities Modernization Act S. 185, Promise for Antibiotics and Therapeutics for Health Act S. 2713, Advancing Precision Medicine Act of 2016 S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act S. 2742, Promoting Biomedical Research and Public Health for Patients Act Opioid abuse legislation. H.R.2872, Opioid Addiction Treatment Modernization Act H.R.3537, Synthetic Drug Control Act of 2015 H.R.2536/S.1455, Recovery Enhancement for Addiction Treatment Act TREAT Act H.R.2805, Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 H.R.3014, Medical Controlled Substances Transportation Act of 2015 H.R.3716, Ensuring Terminated Providers are Removed from Medicaid and CHIP Act H.R.3821, Medicaid DOC Act H.R.2646, Helping Families in Mental Health Crisis Act of 2015 S.524, Comprehensive Addiction and Recovery Act of 2016 H.R.4396, Heroin and Prescription Drug Abuse Prevention and Reduction Act S.2256, Co-Prescribing Saves Lives Act of 2015 S.480, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015 S.2680, Mental Health Reform Act of 2016 S.2687, Plan of Safe Care Improvement Act S.2423/H.R.4447, Opioid and Heroin Epidemic Emergency Supplemental Appropriations Act S.1455/H.R.2536, Recovery Enhancement for Addiction Treatment Act (TREAT Act) H.R.5046, Comprehensive Opioid Abuse Reduction Act of 2016 H.R.3680, Co-Prescribing to Reduce Overdoses Act of 2016 H.R.4981, Opioid Use Disorder Treatment Expansion and Modernization Act H.R.3691, Improving Treatment for Pregnant and Postpartum Women Act of 2016 H.R.4586, Lali's Law H.R.4976, Opioid Review Modernization Act of 2016 H.R.4599, Reducing Unused Medications Act of 2016 H.R.4969, John Thomas Decker Act of 2016 H.R.4641, To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes. H.R.4978, NAS Healthy Babies Act H.R.3691, Improving Treatment for Pregnant and Postpartum Women Act of 2016 H.R.4229/S.36, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015

Client expense: Not reported · Firm income: $20,000

H.R.4229

EDWARD LONG KATHERINE VANLANDINGHAM

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

AMERICAN MEDICAL ASSOCIATIONclient→AMERICAN MEDICAL ASSOCIATION

2016 · first_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 1270, Restoring Access to Medication Act of 2015, all provisions S. 709, Restoring Access to Medication Act of 2015, all provisions S. 524, Comprehensive Addiction and Recovery Act of 2015, all provisions S. 2256, Co-Prescribing Saves Lives Act of 2015, all provisions S. 2687, Plan of Safe Care Improvement Act, all provisions S. 2680, Mental Health Reform Act of 2016, all provisions S. 1945, Mental Health Reform Act of 2015, all provisions H.R. 2646, Helping Families in Mental Health Crisis Act of 2015, all provisions H.R. 1725, National All Schedules Prescription Electronic Reporting (NASPER) Reauthorization Act of 2015, all provisions S. 480, National All Schedules Prescription Electronic Reporting (NASPER) Reauthorization Act of 2015, all provisions H.R. 2536, Recovery Enhancement for Addiction Treatment (TREAT) Act, all provisions S. 1455, Recovery Enhancement for Addiction Treatment (TREAT) Act, all provisions H.R. 2872, Opioid Addiction Treatment Modernization Act, all provisions H.R. 4599, Reducing Unused Medications Act of 2016, all provisions S. 2578, Reducing Unused Medications Act of 2016, all provisions H.R. 6, 21st Century Cures Act, all provisions H.R. 293, To amend title XI of the Social Security Act to exempt from manufacturer transparency reporting certain transfers used for educational purposes, and for other purposes, all provisions S. 2511, Improving Health Information Technology Act, all provisions S.2141, TRUST IT Act, all provisions H.R. 4229, Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015, all provisions Prescription Drug Diversion/Opioid Abuse Meaningful Use Regulations/Electronic Health Records Health Savings Accounts - Prescription requirements for over-the-counter medications Medical Licensure - The Interstate Medical Licensure Compact Telemedicine Health system reform Human trafficking Health data security Prescription drug costs Chronic Care Prediabetes Hypertension Indoor Tanning Salons Home Blood Pressure Monitoring equipment Unique Device Identifier inclusion on claim forms FDA/NIH Modernization Sunshine/Open Payments ICD-10 Health Insurance Portability and Accountability Act (HIPAA) Laboratory developed tests (LDTs) Precision Medicine Prescription Drug Monitoring Programs (PDMPs) Zika virus coding

Client expense: $6,600,000 · Firm income: Not reported

H.R. 4229

ANDREW WANKUM CHARLES KELS JASON MARINO KRISTEN O'BRIEN LAURA HOFFMAN LINDSEY BRILL REBECCA AIKEN HACKETT SHANNON CURTIS SYLVIA TRUJILLO TODD ASKEW mr GEORGE COX iii mr JASON SCULL mr MATTHEW REID mr RICHARD DEEM mr THOMAS ROBERGE jr ms CYNTHIA BROWN ms DANA LICHTENBERG ms DEBRA COHN ms KORYN RUBIN ms MARGARET GARIKES

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Science & Technology Policy (OSTP), SENATE, Veterans Affairs, Dept of (VA), White House Office